Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention BeMap, the most common co-covered peer. We currently track 1 Biotech story that mention CGN.SI, all published on February 18, 2026. Each carries 9 original sources on average.
Last mentioned: Feb 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention BeMap, the most common co-covered peer. We currently track 1 Biotech story that mention CGN.SI, all published on February 18, 2026. Each carries 9 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CGN.SI. Shared-story counts are live from our verified record — not editorial picks.
A global surge in pre-market trading on February 18, 2026, has highlighted significant gains for specialized biotech and MedTech entities. Parx Materials and Coltene Holding led the sector's movement as investors pivoted toward antimicrobial innovation and dental technology amid broader market volatility.
CGN.SI is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
